This trial is studying a new treatment for cancer, in which T-cells are collected from the patient, modified with a new genetic material, and then infused back into the patient's body.
3 Primary · 2 Secondary · Reporting Duration: Up to 1 year post T-cell infusion
30 Total Participants · 1 Treatment Group
Primary Treatment: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells · No Placebo Group · Phase 1 & 2
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: